Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

ClinicalTrials.gov ID: NCT00056160

Public ClinicalTrials.gov record NCT00056160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.

Study identification

NCT ID
NCT00056160
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Celgene
Industry
Enrollment
353 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
Oct 31, 2005
Completion
Sep 30, 2008
Last update posted
Oct 18, 2017

2003 – 2008

United States locations

U.S. sites
44
U.S. states
24
U.S. cities
41
Facility City State ZIP Site status
Clinical Research Consultants, Inc. Hoover Alabama 35216
City of Hope National Medical Center Duarte California 91010
UCLA School of Medicine Los Angeles California 90095
UCSF California San Francisco California 94143
Stanford University Medical Center, Division of Hematology Stanford California 94305-5112
Yale University School of Medicine New Haven Connecticut 06520
University of Florida Gainesville Florida 32610
Mayo Clinic- Jacksonville Jacksonville Florida 32224
University of Miami Miami Florida 33136
Oncology Hematology Consultants Sarasota Florida 34239
H Lee Moffitt Cancer Center Tampa Florida 33612-9497
Emory University Atlanta Georgia 30322
Medical College of Georgia Augusta Georgia 30912-3125
Northwestern University Med Ctr Chicago Illinois 60611-2927
Rush Cancer Institute Section of Hematology Chicago Illinois 60612-3824
Loyola University Medical Center Maywood Illinois 60153
Indiana Cancer Research Institute Indianapolis Indiana 46202-5254
University of Iowa Hospital Clinic Iowa City Iowa 52242
Ocshner Clinical Foundation New Orleans Louisiana 70121
Johns Hopkins Medicine Department of Oncology Baltimore Maryland 21231
Dana Farber Cancer Institute Boston Massachusetts 02115
University Of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic Cancer Center Rochester Minnesota 55905
Washington University School of Medicine- Sherman Cancer Center St Louis Missouri 63110
Hackensack University Medical Center Hackensack New Jersey 07601
Roswell Park Cancer Institute Buffalo New York 14263
St. Vincent's Comprehensive Cancer Center New York New York 10011
New York Presbyterian Hospital New York New York 10021
SUNY Upstate Medical University Syracuse New York 13210
MBCCOP Our Lady of Mercy Cancer Center New York Medical College The Bronx New York 10466
Duke University Medical Center Durham North Carolina 27710
Wake Forest University School of Medicine Winston-Salem North Carolina 27157-1023
Cleveland Clinic Myeloma Program Cleveland Ohio 44195
Ohio State University Columbus Ohio 43210
Kaiser Permanente Northwest Region Center for Health Research Portland Oregon 97227
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104
University of Pittsburgh Pittsburgh Pennsylvania 15213
Charleston Hematology/Oncology P.A. Charleston South Carolina 29403
Medical University of SC Charleston South Carolina 29425
South Carolina Oncology Group West Columbia South Carolina 29169
Sarah Cannon Cancer Center Nashville Tennessee 37203-1632
MD Anderson Cancer Center Houston Texas 77030-4009
Froedtert Hospital/BMT Medical College of Wisconsin Milwaukee Wisconsin 53226-3522

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00056160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 18, 2017 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00056160 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →